Getting a dementia diagnosis is rarely a simple process. There is no single blood test that confirms it, no imaging scan that catches every case early, and no two evaluations that look exactly alike. For families navigating this for the first time, the process can feel confusing and drawn out at a moment when clarity is exactly what everyone is looking for.
Understanding how dementia is actually diagnosed, what the steps involve and why they exist, can make the experience less disorienting and help families ask better questions along the way.
Why Diagnosis Is Complex
Dementia is diagnosed clinically, meaning it is based on a combination of symptoms, history, test results, and the judgment of a clinician experienced in cognitive disorders. Unlike many medical conditions where a single definitive test produces a yes or no answer, dementia diagnosis requires ruling out other causes of cognitive change, characterizing the pattern of impairment, and building a picture of how symptoms have developed over time.
A 2024 narrative review published in PMC by researchers examining neuropsychological assessment in dementia noted that dementia remains significantly underdiagnosed, partly because early indicators of cognitive decline are subtle and can be attributed to other causes, and partly because the evaluation process requires access to specialists that not everyone can easily reach. Getting to a correct diagnosis, and particularly to a specific diagnosis of dementia subtype, often takes time and more than one clinical encounter.
The Starting Point: Primary Care
For most families, the diagnostic process begins with a primary care physician. Someone notices that a parent is repeating themselves, getting lost in familiar places, struggling to manage finances, or behaving uncharacteristically. They bring it up at a routine appointment, or the physician notices something during an exam.
At this stage, the primary care physician will typically conduct a brief cognitive screening. The most commonly used tools are the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), both of which are short structured tests that assess orientation, memory, attention, language, and visuospatial ability. These are screening instruments, not diagnostic tools. A low score signals that further evaluation is warranted. A normal score does not definitively rule out early dementia, particularly in highly educated individuals who may compensate well on brief tests.
The primary care visit also typically includes blood work to rule out reversible causes of cognitive symptoms. Thyroid dysfunction, vitamin B12 deficiency, folate deficiency, anemia, infections, and certain medication interactions can all cause cognitive changes that resemble dementia but are treatable. These are worth checking before assuming a neurodegenerative cause.
Referral to a Specialist
If screening raises concern and reversible causes have been excluded, the next step is typically a referral to a neurologist, geriatrician, or geriatric psychiatrist with experience in cognitive disorders. Many academic medical centers have dedicated memory clinics that specialize in this kind of evaluation.
The specialist evaluation is considerably more detailed than what happens in primary care. It usually involves three main components: a clinical interview, neuropsychological testing, and brain imaging.
The clinical interview covers the person’s full cognitive and medical history, the nature and timeline of symptoms, their impact on daily functioning, family history of dementia, current medications, and mood and behavioral changes. Crucially, it includes a separate interview with a family member or close caregiver who can provide an outside perspective on how the person has changed. Collateral history from someone who knows the patient well is clinically important because people with dementia often have limited awareness of their own deficits.
Neuropsychological testing is the most comprehensive part of the evaluation and can take several hours. A neuropsychologist administers a battery of standardized tests that assess multiple cognitive domains in detail: episodic memory, working memory, processing speed, attention and concentration, language, executive function, and visuospatial ability. The pattern of strengths and weaknesses across these domains helps clinicians identify which type of dementia is most likely. A 2024 review published in Frontiers in Human Neuroscience noted that while neuropsychological tests are strong predictors of overall cognitive severity, their ability to differentiate between dementia subtypes varies, which is one reason imaging and biomarkers are increasingly used alongside them.
Brain imaging is typically ordered as part of a comprehensive dementia workup. Structural MRI is the most commonly used modality and allows clinicians to assess brain volume, identify areas of atrophy, detect signs of vascular disease, and rule out other causes of cognitive symptoms such as tumors, normal pressure hydrocephalus, or subdural hematomas. A 2025 update published in PubMed on MRI in dementia diagnosis noted that high-field MRI now allows detection of early structural changes indicative of dementia, and that established scoring systems help quantify findings like hippocampal atrophy in Alzheimer’s disease.
Advanced Biomarker Testing
For cases where the diagnosis remains uncertain after clinical evaluation and standard imaging, or where early and precise diagnosis is particularly important, advanced biomarker testing may be recommended.
PET scanning can detect amyloid plaques and tau tangles in the living brain, the two hallmark proteins of Alzheimer’s disease. Until recently, PET scans were largely confined to research settings, but Medicare coverage decisions have expanded clinical access. A 2023 to 2024 study at the University of California San Francisco Memory and Aging Center found that amyloid PET imaging had a meaningful effect on diagnostic accuracy and clinical decision-making in a real-world memory clinic setting, changing management in a significant proportion of cases.
Cerebrospinal fluid biomarkers, obtained through lumbar puncture, can also detect amyloid and tau levels and are used in some centers as an alternative or complement to PET imaging. Blood-based biomarker tests, particularly plasma phosphorylated tau, are an active area of research and are increasingly available in clinical settings. These tests have the potential to significantly simplify and accelerate early diagnosis, though their clinical use is still evolving.
What the Diagnosis Actually Looks Like
At the end of this process, the clinician will typically provide a diagnosis that includes whether dementia is present, what subtype is most likely, and how severe the impairment currently is. In some cases, the conclusion may be mild cognitive impairment rather than dementia, meaning there are measurable deficits that do not yet meet the threshold for a dementia diagnosis. In other cases, the evidence may point clearly to Alzheimer’s disease, vascular dementia, or another specific type.
It is worth knowing that a definitive confirmation of Alzheimer’s pathology has historically required autopsy, though biomarker testing has substantially narrowed that gap. Clinical diagnosis of Alzheimer’s disease by experienced specialists at memory centers is now quite accurate, but the degree of certainty varies by case and by what testing has been done.
Families should feel entitled to ask the diagnosing clinician several specific questions: What is the diagnosis and what is the evidence for it? What stage or severity is it currently? What symptoms or changes should prompt a follow-up? What are the next recommended steps for treatment and care planning? And if the diagnosis is uncertain, what additional testing might clarify it?
Why Early Diagnosis Matters
There is sometimes reluctance to pursue a formal diagnosis, particularly when someone is still functioning reasonably well and the family fears what a diagnosis might mean. That reluctance is understandable, but early diagnosis has real practical value.
It opens access to medications that may slow symptom progression in early stages. It allows the person with dementia to participate in decisions about their own care while they still have the capacity to do so. It gives families time to plan financially and legally before a crisis forces rushed decisions. And it may open the door to clinical trial participation, which can provide access to emerging treatments and contribute to research that benefits future patients.
Dementia is not easier to manage because it went undiagnosed longer. The earlier families understand what they are dealing with, the more options they have.
If you are trying to understand what dementia actually does to the brain and why these symptoms develop in the first place, our post on the neuroscience of dementia explains the underlying biology in plain language, including how different types of dementia damage different brain regions and produce different patterns of symptoms.
Have questions about memory care for a loved one?
We are happy to talk. Whether you are just starting to research your options or are further along in the process, reach out anytime.
463-444-9064 | Ben@HonorHavenSeniorLiving.com | Schedule a Tour
Sources
- Pirrotta F, et al. Neuropsychological Assessment for Early Detection and Diagnosis of Dementia: Current Knowledge and New Insights. Diagnostics. 2024;14(12):1281.
- Dyrba M, et al. MRI for diagnosing dementia: update 2025. RoFo. 2025.
- Altomare D, et al. Rethinking neuropsychological test validity in dementia assessment: a critical review in the age of neuroimaging and digital markers. Frontiers in Human Neuroscience. 2025;19:1578648.
- Belder CRS, et al. Case-based review of amyloid PET negative cases in a large memory clinic: considerations for differential diagnosis. Alzheimer’s & Dementia. 2024.
- Jack CR Jr, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia. 2018;14(4):535-562.
- Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia. 2024.